Sentence: Merimepodib ( MMPD ) is an orally administered , inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C ( CHC ) when combined with pegylated interferon alfa 2a ( Peg-IFN-alfa-2a ) and ribavirin ( RBV ) .
Drug combination annotation:
[{'class': 'POS', 'spans': ['interferon alfa', 'ribavirin', 'Merimepodib'], 'is_context_needed': False}]